Nektar Therapeutics (NASDAQ:NKTR) SVP Stephen K. Doberstein sold 1,701 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total transaction of $32,863.32. Following the sale, the senior vice president now owns 31,102 shares of the company’s stock, valued at $600,890.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Nektar Therapeutics (NASDAQ NKTR) traded down 2.06% on Friday, hitting $18.04. 1,075,725 shares of the stock were exchanged. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.88. The company’s market cap is $2.82 billion. The firm’s 50-day moving average is $20.56 and its 200-day moving average is $18.57.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. The firm had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.36) EPS. On average, equities analysts forecast that Nektar Therapeutics will post ($0.94) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 1,701 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/18/insider-selling-nektar-therapeutics-nktr-svp-sells-1701-shares-of-stock.html.

A number of equities research analysts have recently issued reports on NKTR shares. Roth Capital set a $31.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Monday, May 22nd. Jefferies Group LLC reduced their price target on shares of Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, May 10th. Aegis reiterated a “buy” rating and set a $27.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, May 10th. BidaskClub upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Tuesday, August 1st. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.10.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTR. Flinton Capital Management LLC raised its position in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 692 shares in the last quarter. Meadow Creek Investment Management LLC raised its position in Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 616 shares in the last quarter. LS Investment Advisors LLC raised its position in Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares in the last quarter. Finally, Glen Harbor Capital Management LLC raised its position in Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 784 shares in the last quarter. Hedge funds and other institutional investors own 93.02% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.